文献速递前列腺癌

GnRH拮抗剂与激动剂对转移性前列腺癌安全性和肿瘤学结局的差异影响:随机对照试验Meta分析

Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · Eur Urol · 2020-06-27

该Meta分析纳入8项随机对照试验共2632例转移性前列腺癌患者,比较GnRH拮抗剂与激动剂的临床安全性和肿瘤学结局。结果显示拮抗剂组总体死亡率(RR 0.48,95%CI 0.26-0.90,p=0.02)和心血管事件(RR 0.52,95%CI 0.34-0.80)显著低于激动剂组,但注射部位反应更高(38% vs 4.8%)。

要点

  • GnRH拮抗剂较激动剂显著降低总体死亡率(RR 0.48,95%CI 0.26-0.90,p=0.02)。
  • 拮抗剂心血管事件更少(RR 0.52,95%CI 0.34-0.80),但注射部位反应更高(38% vs 4.8%)。
  • PSA进展无显著差异,治疗中出现不良事件拮抗剂组73% vs 激动剂组68%(RR 1.10,95%CI 1.04-1.15)。

核心结论

  • GnRH拮抗剂与激动剂相比,总体死亡率和心血管事件显著更低,但注射部位反应更高。

研究设计与样本

  • 遵循PRISMA指南的Meta分析,检索MEDLINE、Web of Science、Cochrane Library和Scopus数据库。
  • 纳入8项随机对照试验(20篇已发表研究),共2632例男性,其中1646例接受GnRH拮抗剂,986例接受GnRH激动剂。

主要发现

  • 治疗中出现的不良事件在拮抗剂组为73%,激动剂组为68%(RR 1.10,95%CI 1.04-1.15)。
  • 严重不良事件在拮抗剂组为9.8%,激动剂组为11%(RR 0.92,95%CI 0.73-1.17)。
  • 拮抗剂组注射部位反应率为38%,激动剂组为4.8%。
  • 拮抗剂组心血管事件更少(RR 0.52,95%CI 0.34-0.80)。
  • 拮抗剂组总体死亡率更低(RR 0.48,95%CI 0.26-0.90,p=0.02),PSA进展无显著差异。

关键数值与推荐

  • 治疗中出现的不良事件:拮抗剂73% vs 激动剂68%,RR 1.10(95%CI 1.04-1.15)。
  • 严重不良事件:拮抗剂9.8% vs 激动剂11%,RR 0.92(95%CI 0.73-1.17)。
  • 心血管事件:RR 0.52(95%CI 0.34-0.80),总体死亡率:RR 0.48(95%CI 0.26-0.90,p=0.02)。

临床怎么用

  • 对于转移性前列腺癌患者,GnRH拮抗剂可能降低死亡和心血管事件风险,但需注意注射部位反应。
  • 选择GnRH拮抗剂或激动剂时应综合评估心血管风险与注射部位耐受性。

局限性

  • 纳入试验随访时间短,心血管事件为次要终点,解释结果需谨慎。
  • 需要进一步研究验证或反驳这些观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Androgen deprivation therapy is the mainstay treatment of metastatic prostate cancer, achieved mainly by gonadotropin-releasing hormone (GnRH) agonists or antagonists. OBJECTIVE: To investigate the differential impact of GnRH agonists and antagonists on clinical safety and oncologic outcomes. EVIDENCE ACQUISITION: This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A literature search using the electronic databases (MEDLINE, Web of Science, Cochrane Library, and Scopus) included randomized controlled trials comparing the clinical safety and oncologic outcomes of GnRH agonists and antagonists. The endpoints of interest were the following: (1) treatment-related adverse effects (AEs), (2) prostate-specific antigen (PSA) progression, and (3) overall mortality. The relative risk (RR) was used as the summary statistic, and results were reported with 95% confidence intervals (CIs). EVIDENCE SYNTHESIS: Eight clinical trials (20 published studies) comprising 2632 men met our inclusion criteria; of them, 1646 received GnRH antagonist and 986 had GnRH agonist. Treatment-emerging AEs occurred in 73% patients in the GnRH antagonist group and 68% in the GnRH agonist group (RR: 1.10, 95% CI: 1.04-1.15). Serious AEs occurred in 9.8% of the GnRH antagonist and 11% of the GnRH agonist group (RR: 0.92, 95% CI: 0.73-1.17). Antagonists were associated with higher injection site reaction rates (38%) than agonists (4.8%). GnRH antagonist was associated with fewer cardiovascular events (RR: 0.52, 95% CI: 0.34-0.80). There was no significant difference in PSA progression, but GnRH antagonist was associated with lower overall mortality rates than GnRH agonists (RR: 0.48, 95% CI: 0.26-0.90, p = 0.02). CONCLUSIONS: Existing data indicate that GnRH antagonist use is associated with significantly lower overall mortality and cardiovascular events as compared with agonists. These findings should be interpreted with caution owing to the short follow-up duration and assessment of cardiovascular events as secondary endpoints in the included trials. Further studies are needed to validate or refute these observations. Injection site reactions were significantly higher in the GnRH antagonist group. PATIENT SUMMARY: Gonadotropin-releasing hormone (GnRH) antagonist is associated with lower death rates and cardiovascular events than GnRH agonists, based on the data from trials with short follow-up duration. GnRH agonists are associated with lower adverse events, such as decreased libido, hot flushes, erectile dysfunction, back pain, weight gain, constipation, and injection site reactions. There were no significant differences in prostate-specific antigen progression or fatigue.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Abufaraj M, Iwata T, Kimura S, et al. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. Eur Urol. 2020. PMID: 32605859. doi:10.1016/j.eururo.2020.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。